Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
AbbVie has accelerating defensive healthcare momentum, with Q1 2026 revenue of $15.0B, adjusted EPS up 7.7%, raised full-year 2026 EPS guidance to $14.08-$14.28, FDA approval of DECNUPAZ, filings for SKYRIZI and upadacitinib, clinical data readouts, and about 12.7% price strength over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Profitability ⢠High Leverage ⢠Negative Equity ABBV delivers strong margins and cash flow, but elevated leverage, negative equity, weak working capital, and premium valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong rebound ⢠Key resistance ⢠Support holding Support Level: $248.78â$250.00 Resistance Level: $264.00â$266.00 ABBV is cautiously constructive after rebounding from $248.78â$250 support last month, but a decisive break above $264â$266 resistance is needed to sustain upside.
Sentiment & News
Key News Insights: ⢠Post-Humira Transition ⢠Pipeline Expansion ⢠Institutional Buying AbbVie's growth outlook is increasingly supported by Skyrizi, Rinvoq and pipeline expansion, though Humira erosion and near-term acquisition dilution remain risks.
AI Summary
ABBV's post-Humira transition is succeeding, but the stock now hinges on Skyrizi/Rinvoq sustaining exceptional growth while neuroscience diversifies the earnings base; with limited valuation upside and high leverage, investors should hold or accumulate only on evidence of continued immunology outperformance and deleveraging.
Description
AbbVie Inc. is a global pharmaceutical company that discovers, develops, manufactures and markets prescription drugs across immunology, oncology, neuroscience, virology and eye care. Its portfolio includes established biologics and small-molecule therapies for conditions such as autoimmune diseases, cancer, hepatitis C, Parkinsonâs and glaucoma, alongside specialty products for endocrine and gastrointestinal disorders. The company was incorporated in 2012, is headquartered in North Chicago, Illinois, and maintains external research collaborations, including an agreement with Dragonfly Therapeutics.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 26 | Jul 3 | ABBV | AbbVie Inc. | AbbVie has accelerating defensive healthcare momentum, with Q1 2026 revenue of $15.0B, adjusted EPS up 7.7%, raised full-year 2026 EPS guidance to $14.08-$14.28, FDA approval of DECNUPAZ, filings for SKYRIZI and upadacitinib, clinical data readouts, and about 12.7% price strength over 21 trading days. | Closed | +3.0% |
| Sep 29 | Oct 6 | ABBV | AbbVie Inc. | AbbVie beat Q2 2025 earnings with raised full-year guidance based on strong sales of key drugs, pipeline advancements, and a 6% dividend increase. The ~6% recent price rise and moderate upward technical momentum, despite nearing resistance, point to moderate near-term capital appreciation potential. | Closed | +3.1% |